Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in
Advertisement

Denali Therapeutics Inc. DNLI

Set alert

Price alert · DNLI

All alert types
18.94 USD -0.38 -1.97%

At close · Oct 30

19.00 +0.06 +0.32%

After hours · Oct 30, 4:59 PM ET

Bid
18.94 × 2
Ask
18.95 × 2
18.64 Day range 19.63
14.41 52-week range 27.21
YTD
+14.72%
1 year
+15.63%
Open
19.25
Prev close
19.32
Mkt cap
3.03B
Vol
1.31M
Avg vol
1.57M
EPS
-2.84
P/E
0.00
Div yield
0.00%
More statistics
Low
18.64
High
19.63
Forward P/E
-7.84
Beta
1.02
Short ratio
7.76
Inst. own
101.32%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
20.76
200-d avg
21.23
1y target
35.50

1M chart

Chart tools
Interval
1m5m15m30m

Signals (6)
NameDateAgo
SMA: BullishOct 20, 20261 week ago
MACD: Buy SignalOct 20, 20261 week ago
RSI: OversoldOct 14, 20262 weeks ago
RSI: OversoldOct 8, 20263 weeks ago
MACD: Sell SignalOct 7, 20263 weeks ago
SMA: BearishOct 1, 20261 month ago

Key statistics

Financials
Market cap
3.03B
Enterprise value
2.42B
Trailing P/E
0.00
Forward P/E
-7.84
PEG ratio
0.00
Price / sales
840.04
Price / book
3.62
EPS (TTM)
-2.84
Beta
1.02
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
3.60M
Revenue growth
0.00%
Free cash flow
-268.53M
Total cash
710.47M
Total debt
37.69M
Return on equity
-54.93%
Shares outstanding
159.85M
Short % of float
10.21%
50-day average
20.76
200-day average
21.23

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 35.50 +87.4% upside
Target (low)
23.00
Target (mean)
35.50
Target (high)
42.00
Ratings (0m) 20 19 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy17
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

Nov 3, 2026

Expected Nov 3, 2026. Consensus EPS estimate -0.36666.

Earnings history

Financials — quick view

All financials
DNLI Revenue — quarterly 3.60M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNLI Net income — quarterly -127.55M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
DNLI EPS — quarterly -0.68
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

DNLI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 3, 2026Sep 30, 2026-0.3222———
Aug 6, 2026Jun 30, 2026-0.51305-0.68-0.17-32.54%
May 7, 2026Mar 31, 2026-0.73-0.69+0.04+5.48%
Feb 26, 2026Dec 31, 2025-0.75-0.73+0.02+2.67%
Nov 6, 2025Sep 30, 2025-0.76-0.74+0.02+2.63%
Aug 11, 2025Jun 30, 2025-0.74-0.72+0.02+2.70%

Upgrades / downgrades

DNLI analyst upgrades and downgrades
DateFirmActionFromTo
Aug 25, 2026B. Riley SecuritiesmainBuyBuy
Aug 7, 2026UBSmainBuyBuy
Jul 23, 2026Morgan StanleymainOverweightOverweight
Jul 16, 2026Deutsche BankmainBuyBuy
May 26, 2026Morgan StanleymainOverweightOverweight
May 14, 2026Morgan StanleymainOverweightOverweight

About Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
denalitherapeutics.com

News

All news

Your note

Sign in to keep a note on DNLI — it syncs with the Stock Master app.

Insider holders

DNLI insider holders
InsiderRelationLatest transactionDateShares held
BAKER BROS ADVISORS, L.P.Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 2, 20260
CHIN PETER SCOTTOfficerSaleSep 3, 2026204,538
FLATLEY JAY TDirectorStock Award(Grant)Jun 2, 2026358,941
HO CAROLEOfficerSaleAug 12, 2025424,804
KROGNES STEVE EDirectorStock Award(Grant)Jun 2, 2026819,999
SATO VICKI LEEDirectorSaleJan 1, 2025107,976

Institution ownership

DNLI institution ownership
Holder% heldSharesValueReported
T. Rowe Price Investment Management, Inc.10.12%16,178,963306.43MJun 29, 2026
Blackrock Inc.8.77%14,026,413265.66MJun 29, 2026
BAILLIE GIFFORD & CO7.48%11,960,230226.53MJun 29, 2026
State Street Corporation4.41%7,049,304133.51MJun 29, 2026
Temasek Holdings (Private) Ltd4.39%7,012,974132.83MSep 29, 2026
Vanguard Portfolio Management LLC4.05%6,477,057122.68MJun 29, 2026

Fund ownership

DNLI fund ownership
Holder% heldSharesValueReported
T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App3.11%4,966,70094.07MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.68%4,288,39181.22MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.39%3,813,51572.23MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.94%3,097,18358.66MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF1.91%3,055,33157.87MSep 29, 2026
VANGUARD WORLD FUND-Vanguard U.S. Growth Fund1.90%3,037,85757.54MMay 30, 2026
Advertisement